Farmacie pro praxi. 2023;19(1):8-10 [Klin Farmakol Farm. 2022;36(2):77-80]

Vericiguat: pharmacological profile

Karel Urbánek
Ústav farmakologie LF UP a FN Olomouc

Vericiguat is a new drug for the treatment of chronic heart failure. It acts as a direct sGS stimulator whose activity is not dependent on the presence of NO. It is administered orally once daily at doses of 2.5, 5 and 10 mg with gradual upward titration. It is metabolized by hepatic glucuronidases UGT1A9 and 1A1 to inactive N-glucuronide. Approximately 53 % of the administered dose is excreted in the urine, while 45% in the faeces. The biological elimination half-life in healthy volunteers averaged 20 hours and in patients with heart failure averaged 30 hours. Its most common adverse effect with an incidence of about 16% is hypotension. It has minimal potential for drug interactions.

Keywords: vericiguat, heart failure, pharmacodynamics, pharmacokinetics.

Published: March 3, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánek K. Vericiguat: pharmacological profile. Pharmacy for Practice. 2023;19(1):8-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017;60(12):5146-5161. Go to original source...
    2. Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. Annu Rev Biochem. 2012;81:533-559. Go to original source... Go to PubMed...
    3. Pieske B, Butler J, Filippatos G, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16(9):1026-1038. Go to original source...
    4. Boettcher M, Thomas D, Mueck W, Loewen S, Arens E, Yoshikawa K, Becker C. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. Eur J Clin Pharmacol. 2021;77(4):527-537. Go to original source...
    5. Ruehs H, Klein D, Frei M, Grevel J, Austin R, Becker C, Roessig L, Pieske B, Garmann D, Meyer M. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. Clin Pharmacokinet. 2021;60(11):1407-1421. Go to original source...
    6. Boettcher M, Düngen HD, Donath F, Mikus G, Werner N, Thuermann PA, Karakas M, Besche N, Koch T, Gurniak M, Becker C. Vericiguat in Combination with Short-Acting Nitroglycerin in Patients With Chronic Coronary Syndromes: The Randomized, Phase Ib, VENICE Study. Clin Pharmacol Ther. 2022;111(6):1239-1247. Go to original source...
    7. Boettcher M, Loewen S, Gerrits M, Becker C. Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers. Clin Pharmacokinet. 2021;60(3):337-351. Go to original source...
    8. Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119-1127. Go to original source... Go to PubMed...
    9. Gheorghiade M, Greene SJ, Butler J, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314(21):2251-2262. Go to original source...
    10. Armstrong PW, Pieske B, Anstrom KJ, et al. VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. Go to original source...
    11. Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313-1321. Go to original source...
    12. Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail. 2021;23(8):1300-1312. Go to original source...
    13. Ezekowitz JA, O'Connor CM, Troughton RW, et al. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure with Reduced Ejection Fraction Study. JACC Heart Fail. 2020;8(11):931-939. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.